Mechanisms of myeloid cell modulation of atherosclerosis

Microbiology Spectrum

Volumn 4, Issue 4, 2016, Pages

  Swirski, Filip K ^a   Nahrendorf, Matthias ^a   Libby, Peter ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL; ATHEROSCLEROSIS; BONE MARROW CELL; COMPLICATION; HUMAN; PATHOLOGY; PHYSIOLOGY; THROMBOSIS;

ANIMALS; ATHEROSCLEROSIS; HUMANS; MYELOID CELLS; THROMBOSIS;

EID: 85011545442     PISSN: None     EISSN: 21650497     Source Type: Journal    
DOI: 10.1128/microbiolspec.MCHD-0026-2015     Document Type: Article

References (84)

1. Osler W. 1892. The Principles and Practice of Medicine. D. Appleton and Company, New York, NY.
2. Rokitansky K. 1855. A Manual of Pathological Anatomy, vol IV, p 201-208. Blanchard and Lea, Philadelphia, PA.
3. Virchow R. 1858. Cellular Pathology. John Churchill, London, United Kingdom.
4. Benditt EP, Benditt JM. 1973. Evidence for a monoclonal origin of human atherosclerotic plaques. Proc Natl Acad Sci U S A 70:1753-1756.
5. Ross R, Glomset JA. 1973. Atherosclerosis and the arterial smooth muscle cells. Science 180:1332-1339.
6. Ross R, Glomset J, Kariya B, Harker L. 1974. A platelet-dependent serum factor that stimulates the proliferation of arterial smooth muscle cells in vitro. Proc Natl Acad Sci U S A 71:1207-1210.
7. Anitschkow N, Chalatow S. 1983. On experimental cholesterin steatosis and its significance in the origin of some pathological processes (1913). Arteriosclerosis 3:178-182.
8. Steinberg D. 2013. In celebration of the 100th anniversary of the lipid hypothesis of atherosclerosis. J Lipid Res 54:2946-2949.
9. Ross R, Harker L. 1976. Hyperlipidemia and atherosclerosis. Science 193:1094-1100.
10. Poole JC, Florey HW. 1958. Changes in the endothelium of the aorta and the behaviour of macrophages in experimental atheroma of rabbits. J Pathol Bacteriol 75:245-251.
11. Joris I, Zand T, Nunnari JJ, Krolikowski FJ, Majno G. 1983. Studies on the pathogenesis of atherosclerosis. I. Adhesion and emigration of mononuclear cells in the aorta of hypercholesterolemic rats. Am J Pathol 113:341-358.
12. Gerrity RG. 1981. The role of the monocyte in atherogenesis: I. Transition of blood-borne monocytes into foam cells in fatty lesions. Am J Pathol 103:181-190.
13. Faggiotto A, Ross R. 1984. Studies of hypercholesterolemia in the nonhuman primate. II. Fatty streak conversion to fibrous plaque. Arteriosclerosis 4:341-356.
14. Faggiotto A, Ross R, Harker L. 1984. Studies of hypercholesterolemia in the nonhuman primate. I. Changes that lead to fatty streak formation. Arteriosclerosis 4:323-340.
15. Libby P. 1990. Inflammatory and immune mechanisms in atherogenesis, p 79-89. In Leaf A, Weber P (ed), Atheroclerosis Reviews, vol 21. Raven Press, New York, NY.
16. Hansson GK, Jonasson L. 2009. The discovery of cellular immunity in the atherosclerotic plaque. Arterioscler Thromb Vasc Biol 29:1714-1717.
17. Libby P. 2012. Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol 32:2045-2051.
18. Kannel WB, Dawber TR, Kagan A, Revotskie N, Stokes J, III. 1961. Factors of risk in the development of coronary heart disease-six year follow-up experience. The Framingham Study. Ann Intern Med 55:33-50.
19. Brown MS, Goldstein JL. 1986. A receptor-mediated pathway for cholesterol homeostasis. Science 232:34-47.
20. Steinberg D. 2005. Thematic review series: the pathogenesis of atherosclerosis. An interpretive history of the cholesterol controversy: part II: the early evidence linking hypercholesterolemia to coronary disease in humans. J Lipid Res 46:179-190.
21. Steinberg D. 2004. Thematic review series: the pathogenesis of atherosclerosis. An interpretive history of the cholesterol controversy: part I. J Lipid Res 45:1583-1593.
22. Hansson GK, Libby P, Schönbeck U, Yan ZQ. 2002. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ Res 91:281-291.
23. Libby P, Hansson GK. 2015. Inflammation and immunity in diseases of the arterial tree: players and layers. Circ Res 116:307-311.
24. Libby P. 2013. Collagenases and cracks in the plaque. J Clin Invest 123:3201-3203.
25. Lahoute C, Herbin O, Mallat Z, Tedgui A. 2011. Adaptive immunity in atherosclerosis: mechanisms and future therapeutic targets. Nat Rev Cardiol 8:348-358.
26. Libby P, Ridker PM, Hansson GK. 2011. Progress and challenges in translating the biology of atherosclerosis. Nature 473:317-325.
27. Soehnlein O. 2012. Multiple roles for neutrophils in atherosclerosis. Circ Res 110:875-888.
28. Mestas J, Ley K. 2008. Monocyte-endothelial cell interactions in the development of atherosclerosis. Trends Cardiovasc Med 18:228-232.
29. Munro JM, Cotran RS. 1988. The pathogenesis of atherosclerosis: atherogenesis and inflammation. Lab Invest 58:249-261.
30. O'Brien KD, Allen MD, McDonald TO, Chait A, Harlan JM, Fishbein D, McCarty J, Ferguson M, Hudkins K, Benjamin CD, Lobb R, Alpers C. 1993. Vascular cell adhesion molecule-1 is expressed in human coronary atherosclerotic plaques. Implications for the mode of progression of advanced coronary atherosclerosis. J Clin Invest 92:945-951.
31. Libby P, Li H. 1993. Vascular cell adhesion molecule-1 and smooth muscle cell activation during atherogenesis. J Clin Invest 92:538-539.
32. Murray PJ, Allen JE, Biswas SK, Fisher EA, Gilroy DW, Goerdt S, Gordon S, Hamilton JA, Ivashkiv LB, Lawrence T, Locati M, Mantovani A, Martinez FO, Mege JL, Mosser DM, Natoli G, Saeij JP, Schultze JL, Shirey KA, Sica A, Suttles J, Udalova I, van Ginderachter JA, Vogel SN, Wynn TA. 2014. Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity 41:14-20.
33. Tacke F, Alvarez D, Kaplan TJ, Jakubzick C, Spanbroek R, Llodra J, Garin A, Liu J, Mack M, van RooijenN, Lira SA, Habenicht AJ, RandolphGJ. 2007. Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques. J Clin Invest 117:185-194.
34. Swirski FK, Libby P, Aikawa E, Alcaide P, Luscinskas FW, Weissleder R, Pittet MJ. 2007. Ly-6Chi monocytes dominate hypercholesterolemiaassociated monocytosis and give rise to macrophages in atheromata. J Clin Invest 117:195-205.
35. Woollard KJ, Geissmann F. 2010. Monocytes in atherosclerosis: subsets and functions. Nat Rev Cardiol 7:77-86.
36. Weber C, Zernecke A, Libby P. 2008. The multifaceted contributions of leukocyte subsets to atherosclerosis: lessons from mouse models. Nat Rev Immunol 8:802-815.
37. -/-mice: evidence for independent chemokine functions in atherogenesis. Circulation 117:1642-1648.
38. SoehnleinO, DrechslerM, Döring Y, Lievens D, HartwigH, Kemmerich K, Ortega-Gómez A, MandlM, Vijayan S, Projahn D, Garlichs CD, Koenen RR, Hristov M, Lutgens E, Zernecke A, Weber C. 2013. Distinct functions of chemokine receptor axes in the atherogenic mobilization and recruitment of classical monocytes. EMBO Mol Med 5:471-481.
39. Swirski FK, Pittet MJ, Kircher MF, Aikawa E, Jaffer FA, Libby P, Weissleder R. 2006. Monocyte accumulation in mouse atherogenesis is progressive and proportional to extent of disease. Proc Natl Acad Sci U S A 103:10340-10345.
40. van Gils JM, Derby MC, Fernandes LR, Ramkhelawon B, Ray TD, Rayner KJ, Parathath S, Distel E, Feig JL, Alvarez-Leite JI, Rayner AJ, McDonald TO, O'Brien KD, Stuart LM, Fisher EA, Lacy-Hulbert A, Moore KJ. 2012. The neuroimmune guidance cue netrin-1 promotes atherosclerosis by inhibiting the emigration of macrophages from plaques. Nat Immunol 13:136-143.
41. Wanschel A, Seibert T, Hewing B, Ramkhelawon B, Ray TD, van Gils JM, Rayner KJ, Feig JE, O'Brien ER, Fisher EA, Moore KJ. 2013. Neuroimmune guidance cue Semaphorin 3E is expressed in atherosclerotic plaques and regulates macrophage retention. Arterioscler Thromb Vasc Biol 33:886-893.
42. Swirski FK, Nahrendorf M, Libby P. 2012. The ins and outs of inflammatory cells in atheromata. Cell Metab 15:135-136.
43. Cybulsky MI, Jongstra-Bilen J. 2010. Resident intimal dendritic cells and the initiation of atherosclerosis. Curr Opin Lipidol 21:397-403.
44. + T-cell priming efficacy under hypercholesterolemic conditions associated with atherosclerosis. Circ Res 103:965-973.
45. Gimbrone MA Jr, García-Cardeña G. 2013. Vascular endothelium, hemodynamics, and the pathobiology of atherosclerosis. Cardiovasc Pathol 22:9-15.
46. Chatzizisis YS, Blankstein R, Libby P. 2014. Inflammation goes with the flow: implications for non-invasive identification of high-risk plaque. Atherosclerosis 234:476-478.
47. Jongstra-Bilen J, Haidari M, Zhu SN, Chen M, Guha D, Cybulsky MI. 2006. Low-grade chronic inflammation in regions of the normal mouse arterial intima predisposed to atherosclerosis. J Exp Med 203:2073-2083.
48. Clinton SK, Underwood R, Hayes L, Sherman ML, Kufe DW, Libby P. 1992. Macrophage colony-stimulating factor gene expression in vascular cells and in experimental and human atherosclerosis. Am J Pathol 140:301-316.
49. Stary HC. 1989. Evolution and progression of atherosclerotic lesions in coronary arteries of children and young adults. Arteriosclerosis 9 (Suppl):I19-I32.
50. Rosenfeld ME, Ross R. 1990. Macrophage and smooth muscle cell proliferation in atherosclerotic lesions of WHHL and comparably hypercholesterolemic fat-fed rabbits. Arteriosclerosis 10:680-687.
51. Robbins CS, Hilgendorf I, Weber GF, Theurl I, Iwamoto Y, Figueiredo JL, Gorbatov R, Sukhova GK, Gerhardt LM, Smyth D, Zavitz CC, Shikatani EA, Parsons M, van Rooijen N, Lin HY, Husain M, Libby P, Nahrendorf M, Weissleder R, Swirski FK. 2013. Local proliferation dominates lesional macrophage accumulation in atherosclerosis. Nat Med 19:1166-1172.
52. Geng YJ, Libby P. 1995. Evidence for apoptosis in advanced human atheroma. Colocalization with interleukin-1β-converting enzyme. Am J Pathol 147:251-266.
53. Geng YJ, Libby P. 2002. Progression of atheroma: a struggle between death and procreation. Arterioscler Thromb Vasc Biol 22:1370-1380.
54. Li S, Sun Y, Liang CP, Thorp EB, Han S, Jehle AW, Saraswathi V, Pridgen B, Kanter JE, Li R, Welch CL, Hasty AH, Bornfeldt KE, Breslow JL, Tabas I, Tall AR. 2009. Defective phagocytosis of apoptotic cells by macrophages in atherosclerotic lesions of ob/ob mice and reversal by a fish oil diet. Circ Res 105:1072-1082.
55. Thorp E, Tabas I. 2009. Mechanisms and consequences of efferocytosis in advanced atherosclerosis. J Leukoc Biol 86:1089-1095.
56. Libby P, Tabas I, Fredman G, Fisher EA. 2014. Inflammation and its resolution as determinants of acute coronary syndromes. Circ Res 114:1867-1879.
57. Brogi E, Winkles JA, Underwood R, Clinton SK, Alberts GF, Libby P. 1993. Distinct patterns of expression of fibroblast growth factors and their receptors in human atheroma and nonatherosclerotic arteries. Association of acidic FGF with plaque microvessels and macrophages. J Clin Invest 92:2408-2418.
58. Sluimer JC, Daemen MJ. 2009. Novel concepts in atherogenesis: angiogenesis and hypoxia in atherosclerosis. J Pathol 218:7-29.
59. Rajavashisth T, Qiao JH, Tripathi S, Tripathi J, Mishra N, Hua M, Wang XP, Loussararian A, Clinton S, Libby P, Lusis A. 1998. Heterozygous osteopetrotic (op) mutation reduces atherosclerosis in LDL receptor-deficient mice. J Clin Invest 101:2702-2710.
60. New SE, Goettsch C, Aikawa M, Marchini JF, Shibasaki M, Yabusaki K, Libby P, Shanahan CM, Croce K, Aikawa E. 2013. Macrophagederived matrix vesicles: an alternative novel mechanism for microcalcification in atherosclerotic plaques. Circ Res 113:72-77.
61. Liu J, Sukhova GK, Sun JS, Xu WH, Libby P, Shi GP. 2004. Lysosomal cysteine proteases in atherosclerosis. Arterioscler Thromb Vasc Biol 24:1359-1366.
62. Libby P. 2013. Mechanisms of acute coronary syndromes and their implications for therapy. N Engl J Med 368:2004-2013.
63. Bentzon JF, Otsuka F, Virmani R, Falk E. 2014. Mechanisms of plaque formation and rupture. Circ Res 114:1852-1866.
64. Ueno T, Dutta P, Keliher E, Leuschner F, Majmudar M, Marinelli B, Iwamoto Y, Figueiredo JL, Christen T, Swirski FK, Libby P, Weissleder R, Nahrendorf M. 2013. Nanoparticle PET-CT detects rejection and immunomodulation in cardiac allografts. Circ Cardiovasc Imaging 6: 568-573.
65. Quillard T, Araújo HA, Franck G, Tesmenitsky Y, Libby P. 2014. Matrix metalloproteinase-13 predominates over matrix metalloproteinase-8 as the functional interstitial collagenase in mouse atheromata. Arterioscler Thromb Vasc Biol 34:1179-1186.
66. Quillard T, Araújo HA, Franck G, Shvartz E, Sukhova G, Libby P. 2015. TLR2 and neutrophils potentiate endothelial stress, apoptosis and detachment: implications for superficial erosion. Eur Heart J 36:1394-1404.
67. Megens RT, Vijayan S, Lievens D, Döring Y, van Zandvoort MA, Grommes J, Weber C, Soehnlein O. 2012. Presence of luminal neutrophil extracellular traps in atherosclerosis. Thromb Haemost 107:597-598.
68. Borissoff JI, Joosen IA, Versteylen MO, Brill A, Fuchs TA, Savchenko AS, Gallant M, Martinod K, Ten Cate H, Hofstra L, Crijns HJ, Wagner DD, Kietselaer BL. 2013. Elevated levels of circulating DNA and chromatin are independently associated with severe coronary atherosclerosis and a prothrombotic state. Arterioscler Thromb Vasc Biol 33:2032-2040.
69. Stakos DA, Kambas K, Konstantinidis T, Mitroulis I, Apostolidou E, Arelaki S, Tsironidou V, Giatromanolaki A, Skendros P, Konstantinides S, Ritis K. 2015. Expression of functional tissue factor by neutrophil extracellular traps in culprit artery of acute myocardial infarction. Eur Heart J 36:1405-1414.
70. Warnatsch A, Ioannou M, Wang Q, Papayannopoulos V. 2015. Inflammation. Neutrophil extracellular traps license macrophages for cytokine production in atherosclerosis. Science 349:316-320.
71. Sun J, Sukhova GK, Wolters PJ, Yang M, Kitamoto S, Libby P, MacFarlane LA, Mallen-St Clair J, Shi GP. 2007. Mast cells promote atherosclerosis by releasing proinflammatory cytokines. Nat Med 13:719-724.
72. Libby P, Shi GP. 2007. Mast cells as mediators and modulators of atherogenesis. Circulation 115:2471-2473.
73. + T cells, mast cells, and macrophages participate in the pathogenesis of experimental abdominal aortic aneurysms. EMBO Mol Med 6:952-969.
74. Bot I, de Jager SC, Zernecke A, Lindstedt KA, van Berkel TJ, Weber C, Biessen EA. 2007. Perivascular mast cells promote atherogenesis and induce plaque destabilization in apolipoprotein E-deficient mice. Circulation 115:2516-2525.
75. Willems S, Vink A, Bot I, Quax PH, de Borst GJ, de Vries JP, van de Weg SM, Moll FL, Kuiper J, Kovanen PT, de Kleijn DP, Hoefer IE, Pasterkamp G. 2013. Mast cells in human carotid atherosclerotic plaques are associated with intraplaque microvessel density and the occurrence of future cardiovascular events. Eur Heart J 34:3699-3706.
76. Sager HB, Dutta P, Dahlman JE, Hulsmans M, Courties G, Sun Y, Heidt T, Vinegoni C, Borodovsky A, Fitzgerald K, Wojtkiewicz GR, Iwamoto Y, Tricot B, Khan OF, Kauffman KJ, Xing Y, Shaw TE, Libby P, Langer R, Weissleder R, Swirski FK, Anderson DG, Nahrendorf M. 2016. RNAi targeting multiple cell adhesion molecules reduces immune cell recruitment and vascular inflammation after myocardial infarction. Sci Transl Med 8:342ra80.
77. Courties G, Heidt T, Sebas M, Iwamoto Y, Jeon D, Truelove J, Tricot B, Wojtkiewicz G, Dutta P, Sager HB, Borodovsky A, Novobrantseva T, Klebanov B, Fitzgerald K, Anderson DG, Libby P, Swirski FK, Weissleder R, Nahrendorf M. 2014. In vivo silencing of the transcription factor IRF5 reprograms the macrophage phenotype and improves infarct healing. J Am Coll Cardiol 63:1556-1566.
78. Jain MK, Ridker PM. 2005. Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat Rev Drug Discov 4:977-987.
79. Nidorf SM, Eikelboom JW, Budgeon CA, Thompson PL. 2013. Lowdose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol 61:404-410.
80. Everett BM, Pradhan AD, Solomon DH, Paynter N, Macfadyen J, Zaharris E, Gupta M, Clearfield M, Libby P, Hasan AA, Glynn RJ, Ridker PM. 2013. Rationale and design of the Cardiovascular Inflammation Reduction Trial: a test of the inflammatory hypothesis of atherothrombosis. Am Heart J 166:199-207.e15. doi:10.1016/j.ahj.2013.03.018.
81. Ridker PM, Thuren T, Zalewski A, Libby P. 2011. Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am Heart J 162:597-605.
82. Shah PK, Chyu KY, Dimayuga PC, Nilsson J. 2014. Vaccine for atherosclerosis. J Am Coll Cardiol 64:2779-2791.
83. Nilsson J, Lichtman A, Tedgui A. 2015. Atheroprotective immunity and cardiovascular disease: therapeutic opportunities and challenges. J Intern Med 278:507-519.
84. Libby P, Pasterkamp G. 2015. Requiem for the 'vulnerable plaque'. Eur Heart J 36:2984-2987.